Contineum Therapeutics, Inc.
CTNM- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001855175
In the last 90 days, Contineum Therapeutics, Inc. insiders filed 0 open-market purchases and 7 sales; 102 institutions reported holding it in 13F filings for Q2 2026, worth $500.6M in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $1.07M in total
- 7
- 13F holdersQ2 2026, +14 vs. previous quarter
- 102
- 13F valueReported value at the end of Q2 2026
- $500.6M
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Superinvestors holding CTNM, Q2 2026
1 superinvestor reports holding Contineum Therapeutics, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
HHLR Advisors (Hillhouse)
Zhang Lei
1.3%
Contineum Therapeutics, Inc.'s share of the portfolio
- Shares
- 669,337
- Value
- $11.0M
Latest insider trades
Open-market purchases and sales by Contineum Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 8, 2026 (view filing)6:08 PM ET | Sep 8 | Same day | Stengone Carmine N.CEO and President | SSaleClass A Common Stock | −2.50K | $16.46 | −$41.1K | −12.7%17.2K after | 10b5-1 |
| Aug 3, 2026 (view filing)6:14 PM ET | Aug 3 | Same day | Stengone Carmine N.CEO and President | SSaleClass A Common Stock | −2.50K | $16.01 | −$40.0K | −12.7%17.2K after | 10b5-1 |
| Jul 10, 2026 (view filing)5:20 PM ET | Jul 8-9 | 2 days | Lorrain Daniel S.Chief Scientific Officer | SSaleClass A Common Stock | −1.04K | $16.00 | −$16.6K | −0.8%135.2K after | 2 lots10b5-1 |
| Jul 8, 2026 (view filing)6:49 PM ET | Jul 8 | Same day | Stengone Carmine N.CEO and President | SSaleClass A Common Stock | −2.50K | $16.00 | −$40.0K | −12.7%17.2K after | 10b5-1 |
| Jul 2, 2026 (view filing)5:47 PM ET | Jun 30-Jul 1 | 2 days | Lorrain Daniel S.Chief Scientific Officer | SSaleClass A Common Stock | −37.2K | $15.99 | −$594.6K | −21.6%135.2K after | 3 lots10b5-1 |
| Jul 1, 2026 (view filing)7:04 PM ET | Jun 30 | 1 day | Watkins TimCMO & Head of Development | SSaleClass A Common Stock | −10.8K | $16.02 | −$173.6K | −54.7%8.96K after | 10b5-1 |
| Jul 1, 2026 (view filing)7:04 PM ET | Jun 30 | 1 day | Stengone Carmine N.CEO and President | SSaleClass A Common Stock | −10.0K | $16.01 | −$160.1K | −36.7%17.2K after | 10b5-1 |
| Jun 1, 2026 (view filing) | Jun 1 | Same day | Lorrain Daniel S.Chief Scientific Officer | SSaleClass A Common Stock | −4.17K | $13.16 | −$54.9K | −2.9%139.4K after | 10b5-1 |
| May 1, 2026 (view filing) | May 1 | Same day | Lorrain Daniel S.Chief Scientific Officer | SSaleClass A Common Stock | −4.17K | $13.12 | −$54.7K | −2.8%143.5K after | 2 lots10b5-1 |
| Apr 6, 2026 (view filing) | Apr 6 | Same day | Lorrain Daniel S.Chief Scientific Officer | SSaleClass A Common Stock | −4.17K | $13.43 | −$56.0K | −2.7%147.7K after | 10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in Contineum Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Suvretta Capital Management, LLC | 2,841,334 | $46.6M | 0.98% | 00.0% | Unchanged |
| Jupiter Topco LLC | 2,734,836 | $44.8M | 0.02% | +2,734,836 | New |
| BlackRock, Inc. | 2,064,345 | $33.8M | 0.00% | +1,395,222+208.5% | Added |
| Johnson & Johnson | 1,979,173 | $32.4M | 4.06% | 00.0% | Unchanged |
| Franklin Resources Inc | 1,839,227 | $30.1M | 0.01% | 00.0% | Unchanged |
| Balyasny Asset Management LLC | 1,522,793 | $25.0M | 0.05% | −162,842−9.7% | Reduced |
| Vanguard Capital Management LLC | 1,321,356 | $21.7M | 0.00% | +107,183+8.8% | Added |
| Perceptive Advisors LLC | 1,255,592 | $20.6M | 0.32% | 00.0% | Unchanged |
| FMR LLC | 1,040,130 | $17.0M | 0.00% | +225,259+27.6% | Added |
| Millennium Management LLC | 931,709 | $15.3M | 0.01% | −603,740−39.3% | Reduced |